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Summary
Cellular senescence is an effective tumor-suppressive
mechanism that causes a stable proliferative arrest in cells
with potentially oncogenic alterations. Here, we have
investigated the role of the p33ING1 tumor suppressor in
the regulation of cellular senescence in human primary
fibroblasts. We show that p33ING1 triggers a senescent
phenotype in a p53-dependent fashion. Also, endoge-
nous p33ING1 protein accumulates in chromatin in onco-
gene-senescent fibroblasts and its silencing by RNA
interference impairs senescence triggered by oncogenes.
Notably, the ability to induce senescence is lost in a
mutant version of p33ING1 present in human tumors.
Using specific point mutants, we further show that recog-
nition of the chromatin mark H3K4me3 is essential for
induction of senescence by p33ING1. Finally, we demon-
strate that ING1-induced senescence is associated to a
specific genetic signature with a strong representation of
chemokine and cytokine signaling factors, which signifi-
cantly overlaps with that of oncogene-induced senes-
cence. In summary, our results identify ING1 as a critical
epigenetic regulator of cellular senescence in human
fibroblasts and highlight its role in control of gene expres-
sion in the context of this tumor-protective response.
Key words: cellular senescence; chromatin; ING1; p53;
histone marks.
Introduction
Higher organisms possess defense mechanisms that restrain the
ability of cells with potentially oncogenic alterations to progress
to form tumors (Lowe et al., 2004). In this context, cellular
senescence has emerged recently as an antiproliferative tumor-
suppressive mechanism, at a similar level with apoptosis (Prieur
& Peeper, 2008; Collado & Serrano, 2010). Cellular senescence
can be elicited by a series of alterations in normal cellular homeo-
stasis, including telomere dysfunction, DNA damage, oxidative
stress, or aberrant promitogenic signals (Campisi & d’Adda di
Fagagna, 2007; Courtois-Cox et al., 2008). The senescent phe-
notype is defined by several cellular and molecular markers, best
characterized in fibroblasts, including flat extended morphology,
increased heterochromatinization, and a pH-specific Beta-
Galactosidase activity (Senescence-Associated Beta Galactosi-
dase, SA-BetaGal; Dimri et al., 1995; Collado & Serrano, 2006).
Senescence is characterized by a specific gene expression pro-
gram, where epigenetic regulation plays an essential role
(Adams, 2007; Funayama & Ishikawa, 2007; Narita, 2007). The
relevance of oncogene-induced senescence as a tumor-protec-
tive barrier in vivo is now firmly established (Braig et al., 2005;
Chen et al., 2005; Collado et al., 2005; Michaloglou et al.,
2005; Courtois-Cox et al., 2006; Dankort et al., 2007). Senes-
cence is activated in premalignant lesions, as a result of aberrant
mitogenic signals caused by activated oncogenes, blocking pro-
gression to malignant lesions (reviewed in Mooi & Peeper, 2006;
Collado et al., 2007; Courtois-Cox et al., 2008; Prieur & Peeper,
2008). Given the importance of senescence as an effective
tumor-suppressive mechanism, there is an obvious interest in
elucidating the regulatory mechanisms of senescence. The ING
proteins are a family of sequence-conserved proteins, frequently
inactivated in human tumors, which control vital cellular pro-
cesses such as apoptosis, proliferation, or cell migration
(reviewed in Soliman & Riabowol, 2007; Ythier et al., 2008;
Coles & Jones, 2009). ING proteins participate in transcriptional
control via the reading and establishment of chromatin marks
(Champagne & Kutateladze, 2009). In particular, ING proteins
act as specific readers of trimethylated Lysine 4 in histone H3
(H3K4me3), a distinctive mark of active promoters and also take
part in complexes with histone acetyl-transferase (HAT) or de-
acetylase (HDAC) activities (Soliman & Riabowol, 2007). ING pro-
teins have also been connected to the p53 pathway, as
regulators of p53 protein stability and posttranslational modifi-
cation, or as transcriptional cofactors, although there is also evi-
dence for p53-independent functions (Coles & Jones, 2009).
Given the relevance of cellular senescence as an antitumor bar-
rier, we sought to dissect the mechanisms whereby ING1, the
founding member of the ING family, regulates senescence. Our
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data support a critical role for this protein in the circuitry respon-
sible for implementation of senescence, in a p53-dependent
manner, and highlight its role in chromatin control and regula-
tion of gene expression in this context.
Results
p33ING1 induces senescence in human fibroblasts in
a p53-dependent manner
To investigate the role of the ING1 locus in cellular senescence,
we ectopically expressed p33ING1, the major product of the
human ING1 locus (also known as ING1b), in early passage IMR-
90 human fibroblasts. Retroviral transduction was used to
achieve moderate stable expression, to avoid nonphysiological
overexpression. As a control, we used the activated form of the
human Ha-Ras oncogene (RasV12), an extensively characterized
trigger of oncogene-induced senescence in these cells (Serrano
et al., 1997). Enforced expression of ING1 caused a dramatic
reduction in proliferation, as shown by a decrease in thymidine
incorporation or in the number of BrdU-positive cells (Fig. 1A,D).
The inverse correlation between ING1 expression and BrdU
incorporation could also be observed in individual cells by immu-
nofluorescence. Eighty-five percent of AU5-positive cells were
BrdU-negative, while 65% of AU5-negative cells or vector-
infected cells were BrdU-negative, confirming the antiprolifera-
tive effect of ectopic ING1 (Fig. 1B). ING1-expressing fibroblasts
also displayed distinctive markers of cellular senescence, such as
SA-BetaGal activity (Fig. 1C,E), and flat enlarged morphology





Fig. 1 p53-dependent induction of senescence by
ING1. (A) Incorporation of tritiated thymidine in
early passage IMR-90 fibroblasts after retroviral
transduction with vectors expressing p33ING1,
RasV12, or empty vector. The values shown are
relative to vector-infected cells. The average and
SD from three experiments are shown.
(B) Immunofluorescence microscopy showing
expression of AU5-tagged ectopic p33ING1 (AU5)
and BrdU incorporation (BrdU) in IMR-90
fibroblasts infected with the indicated vectors.
Nuclei were counterstained with DAPI. White
arrowheads indicate BrdU-positive, ING1-negative
cells, and yellow arrowheads indicate BrdU-
negative, ING1-positive cells. (C) Representative
micrographs of fibroblasts infected with the
indicated vectors, after detection of SA-BetaGal
activity. (D) Rate of BrdU incorporation of IMR-90
fibroblasts serially infected with the HPV16 E6
oncoprotein (E6) or empty vector, followed by
infection with p33ING1, RasV12, or empty vector,
at day 6 postselection. The average and SD from
three experiments is shown. (E) Percentage of
SA-BetaGal-positive cells, as in panel D. A
representative experiment at day 6 postselection is
shown. (F) Western blot analysis of the indicated
proteins in cells serially infected with E6 and
p33ING1 (ING1) or RasV12 (Ras).
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fibroblasts provokes a cell-cycle arrest with features of cellular
senescence, supporting a causal role for ING1 in the implemen-
tation of this response (see also Goeman et al., 2005). p33ING1,
like other ING proteins, has been functionally linked to the p53
pathway (Coles & Jones, 2009) via mechanisms including control
of p53 protein stability, posttranslational modifications or as
transcriptional cofactors. In human fibroblasts, both the p53
and the p16INK4A-Rb pathway need to be inactivated to bypass
oncogene-induced senescence (Collado et al., 2007). To investi-
gate the functional connection between p33ING1 and p53 in
the context of senescence, we inactivated the p53 pathway in
these cells, using the E6 oncoprotein from human papilloma
virus (Fig. 1F). Ectopic expression of p33ING1 failed to induce a
significant cell-cycle arrest in fibroblasts expressing E6 (Fig. 1D).
Similarly, the induction of the senescence marker SA-BetaGal
by p33ING1 was largely abolished in E6-expressing cells
(Fig. 1E). In agreement with previous reports, inactivation of the
p53 pathway was not sufficient to bypass senescence by RasV12
in these cells (Fig. 1E), which requires additional inactivation of
the Rb pathway (Collado et al., 2007). Interestingly, ING1
increased the level of p21CIP1, a p53 target associated with
senescence. The induction of p21CIP1 by ING1 was lost in E6-
expressing cells (Fig. 1F), in contrast to the effect of Ras on p21,
which is known to be p53-independent (Kivinen et al., 1999).
Thus, p33ING1 induces senescence in human fibroblasts
through a p53-dependent mechanism.
ING1 is essential for oncogene-induced senescence
To gain insights into the involvement of the endogenous
p33ING1 protein in senescence, we analyzed the expression of
ING1 in senescent fibroblasts. We observed a clear increase in
p33ING1 total protein levels in Ras-senescent fibroblasts, relative
to nonsenescent vector-infected fibroblasts (Fig. 2A). The induc-
tion of p33ING1 by oncogenic stress was confirmed using an
inducible system for oncogene-induced senescence, where the
activity of a fusion of the Ras effector MEK with the estrogen
receptor (MEK-ER) can be controlled by addition of 4-hydroxy-
tamoxifen (4-OHT). The levels of p33ING1 increased in 4-OHT-





Fig. 2 Regulation of ING1 during senescence.
(A) Western blot analysis of the p33ING1 protein in
total cell lysates from early passage IMR-90
fibroblasts infected with vectors expressing
p33ING1 (ING1) or RasV12 (Ras), at day 6
postselection. (B) Western blot analysis of the
p33ING1 protein in IMR-90 fibroblasts expressing
MEK with the estrogen receptor 3 days after
addition of 4-hydroxy-tamoxifen (4-OHT).
(C) Western blot analysis of the indicated proteins
in chromatin fractions of IMR-90 cells serially
infected with vectors for E1A and Ras, and the
corresponding empty vectors. Core histones were
detected with Coomassie blue.
(D) Immunofluorescence microscopy of Ras-
senescent or control IMR-90 fibroblasts with an
antibody against ING1. DAPI was used to stain the
nuclei. (E) Quantitative PCR analysis of the
expression of the ING1a and ING1b transcripts in
fibroblasts expressing RasV12 or controls with
empty vector. The average and SD from two
experiments is shown.
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cell-cycle arrest in these cells (data not shown). p33ING1 is a pre-
dominantly nuclear protein that participates in transcriptional
control. Consistent with the results with total lysates, we
observed a clear increase in p33ING1 in the chromatin fraction
of Ras-senescent IMR-90 fibroblasts, in parallel with known
markers of senescent chromatin, like reduced acetylated histone
H3 or increased HMGA histone–like proteins (Narita et al., 2003,
2006) (Fig. 2C; Fig. S1). Significantly, the accumulation of
p33ING1 was abolished in fibroblasts co-expressing RasV12 and
E1A, an adenoviral oncoprotein that allows bypass of oncogene-
induced senescence in these cells by inactivating essential
tumor-suppressive pathways (Serrano et al., 1997). This obser-
vation clearly establishes a link between ING1 accumulation
in chromatin and Ras-induced senescence, and not only Ras
signaling. The accumulation of ING1 in nuclei during oncogene-
induced senescence was further confirmed in immunofluores-
cence experiments, using an anti-ING1 antibody (Fig. 2D). We
analyzed if the increase in p33ING1 protein levels in senescence
could also be observed at the level of RNA. The human ING1
locus encodes two protein products, p33ING1 (encoded by tran-
script ING1b) and p47ING1A (transcript ING1a). Quantitative
PCR analysis did not show a robust increase in the transcript
encoding p33ING1 (transcript ING1b) in Ras-senescent cells
(< 2-fold; Fig. 2E), suggesting that the accumulation of
p33ING1 is mediated by posttranscriptional mechanisms. It has
been reported that p47ING1A RNA and protein increase during
replicative senescence in human fibroblasts (Soliman et al.,
2008). In contrast to this finding, we observed a decrease in the
ING1a-specific transcript in Ras-senescent human fibroblasts
(Fig. 2E). We could not study the p47ING1A protein in this set-
ting, because a specific band corresponding to p47ING1A was
not detectable in our Western blot experiments (data not
shown). Next, we wished to determine whether p33ING1 is a
physiological mediator of oncogene-induced senescence. With
this purpose, we used stable expression of a miR30-based short
hairpin RNA specific for the transcript encoding p33ING1 (tran-
script ING1b), which led to a clear reduction in p33ING1 protein
(Fig. 3A). Vectors encoding sh-ING1b or the empty miR30 back-
bone were introduced into IMR-90 fibroblasts, previously
infected with a MEK-ER vector. Addition of 4-OHT to MEK-ER
fibroblasts resulted in a dramatic reduction in their growth rate,
indicative of induction of senescence (Fig. 3B). In contrast, the
growth of MEK-ER fibroblasts expressing sh-RNA against
p33ING1was not significantly inhibited by 4-OHT, in comparison
with control vehicle, although the shRNA itself inhibited growth
to some degree. Therefore, p33ING1 accumulates in oncogene-
senescent chromatin, and its suppression by RNA interference
impairs oncogene-triggered senescence, supporting a critical
role for this protein in the implementation of this response.
Recognition of chromatin marks is essential for the
induction of senescence by ING1
ING proteins participate in the recognition of the histone mark
H3K4me3 (histone H3 trimethylated in Lysine 4), a feature of
transcriptionally active promoters (Shi et al., 2006; Hung et al.,
2009; Palacios et al., 2008; Pena et al., 2006, 2008; reviewed in
Champagne & Kutateladze, 2009). Structural studies have iden-
tified several residues in the conserved plant homeo domain
(PHD) domain essential for the binding of ING proteins to
H3K4me3 (Pena et al., 2006; Shi et al., 2006). Given the rele-
vance of epigenetic control in gene regulation during senes-
cence (Adams, 2007; Narita, 2007), we decided to investigate
the impact of this feature of ING1 in regulation of senescence.
To this end, we designed mutations in two ING1 residues equiv-
alent to those essential for H3K4me3 binding in ING2 and ING4
(Palacios et al., 2006, 2008; Pena et al., 2006; Shi et al., 2006),
specifically Tyrosine 212 and Tryptophan 235, which were
replaced with Alanines (designated Y212A and W235A, respec-
tively, Fig. 4A). Both mutant p33ING1 proteins were easily
detected after retroviral transduction of IMR-90 fibroblasts,
reaching levels significantly higher than the wild-type form
(Fig. 4B). Immunofluorescence studies also revealed a normal
pattern of subcellular localization, showing nuclear staining with
no obvious differences in the distribution within the nucleus
(Fig. 4C). We investigated the ability of both histone-binding
mutants to induce senescence. In contrast to the reduced prolif-
eration observed in cells with wild-type ING1, fibroblasts
(A)
(B)
Fig. 3 Bypass of oncogene-induced senescence by RNA interference against
p33ING1. (A) Western analysis of p33ING1 protein in IMR-90 fibroblasts
infected with the empty shRNAmir vector LMP (sh-control) or a vector
expression shRNAmir against p33ING1 (sh-ING1b). (B) Growth curves of
IMR90- MEK with the estrogen receptor fibroblasts retrovirally infected with
the indicated shRNAmir vectors, treated with 1 lM 4-hydroxytamoxifen or
ethanol. The number of cells at each time point is represented relative to the
number of cells at day 1. Two independent experiments are shown.
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expressing either of the mutants showed proliferation rates simi-
lar or higher than controls, as measured by BrdU incorporation
or cumulative growth over an 8-day period (Fig. 4D,E). Consis-
tently, expression of the W235A or Y212A mutants did not
cause an increase in the number of SA-BetaGal-positive cells, or
provoked a change in cell morphology, in contrast to wild-type
ING1 (Fig. 4F,G). Oncogenic Ras was used in these assays as a
positive control for senescence induction. These results clearly
indicate that the recognition of histone marks is essential for the








Fig. 4 Recognition of histone marks is essential for ING1-induced senescence. (A) Left, Schematic representation of the p33ING1 protein, indicating the position
of the residues mutated in this work. PIP, PCNA-interacting protein motif; LID, Lamin Interacting Domain; NLS, nuclear localization signal; PHD, plant homeo
domain. Right, Three-dimensional model of the complex of ING1-PHD bound to H3K4me3. ING1 is shown in gray, with the hydrophobic pocket involved in the
binding highlighted in green. The position of the two mutated residues, Y212 andW235, is shown. The N-terminus of H3K4me3 is shown in green in stick
representation. (B) Western blot showing expression of ectopic AU5-p33ING1 (AU5) or total p33ING1 in IMR-90 cells expressing the indicated versions of p33ING1
or RasV12. Tubulin was used as a loading control. (C) Confocal fluorescence images showing subcellular localization of wild-type ING1 (ING1) and the Y212A and
W235A mutants in retrovirally infected IMR-90 cells. Nuclei were stained with DAPI. (D) Rate of BrdU incorporation in IMR-90 cells expressing the indicated
vectors, at day 6 postselection. The average and SD of three independent experiments is shown. (E) Growth curve of IMR-90 cells as in D. The average and SD of
two independent experiments is shown. (F) Percentage of SA-BetaGal-postive cells at day 6 postselection, as in D. A representative experiment is shown.
(G) Micrographs showing the morphology and SA-BetaGal staining in cells infected with the indicated vectors.
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A tumor-associated mutation in ING1 abolishes its
ability to trigger senescence
The ING1 locus is inactivated in a large number of human
tumors, including squamous cell carcinoma, breast cancer, and
melanoma (Nouman et al., 2003; Ythier et al., 2008). The most
frequent alteration of ING1 in tumors is its reduced expression
and ⁄ or aberrant localization. However, a small number of point
missense mutations in ING1 have also been found in human
tumors. To test the impact of cancer-associated mutations in
ING1¢s ability to trigger senescence, we focused on the C215S
mutation found in primary head and neck squamous cell carci-
nomas (HNSCC) and hepatocellular carcinomas (HCC; Gunduz
et al., 2000). The mutated residue (Cys 215) is predicted to play
an essential role in stabilizing the structure of the conserved
PHD domain. We confirmed that an ING1 PHD domain contain-
ing the C215S mutation is essentially unfolded in solution
(Fig. S2; see Data S1 for Methods). To test whether this cancer-
associated mutation in ING1 could impinge in its ability to trigger
senescence, we infected IMR-90 early passage fibroblasts with a
retrovirus expressing the C215S mutant. As with the other
mutants used in this study, the C215S version was easily
detected, reaching levels higher than the wild-type protein
(Fig. 5A) and showed normal nuclear localization (data not
shown). Ectopic expression of this mutant version of ING1 failed
to trigger an antiproliferative response in human fibroblasts
(Fig. 5B). Also, no obvious induction of senescence markers,
such as flat morphology or SA-BetaGal activity, was observed
(Fig. 5C and 5D). Thus, a mutation in ING1 present in human
tumors abolishes ING1-induced senescence. This observation
further strengthens the link between regulation of senescence
by ING1 and its tumor-protective action.
Connection of ING1 with SAHFs
In human fibroblasts, and some other cell types, senescence is
accompanied by the appearance of macroscopic regions of
facultative heterochromatin, known as senescence-associated
heterochromatin foci, or SAHFs (Narita et al., 2003, 2006). The
SAHFs are identified as spots with intense DAPI staining, they
are enriched in heterochromatin markers, such as heterochro-
matin protein1 (HP1) and H3K9me3, and exclude euchromatic
markers, like acetylated histones and H3K4me3 (Narita et al.,
2003, 2006). As the link to transcriptional repression and chro-
matin control appears to be essential for senescence induction
by ING1 (Fig. 4, see also Goeman et al., 2005), we set to investi-
gate the connection between ING1 and the SAHFs. Consistent
with their relative ability to trigger senescence, ectopic expres-
sion of wild-type ING1 led to an increase in SAHF-positive cells, a
robust senescence marker in this cell type, but no increase was
observed after expression of either histone-binding mutant
(Fig. 6A). However, we did not observe a significant accumula-
tion of ectopic or endogenous ING1 in the SAHFs, in immunoflu-
orescence experiments. Consistent with our data showing that
the pro-senescence activity of p33ING1 requires H3K4me3 asso-
ciation, ING1, like H3K4me3, was found excluded from SAHFs
(Figs 6B and S3). Thus, these data reinforce the critical role of
the association between ING1 and H3K4me3 for senescence
induction.
ING1-induced senescence is defined by a specific
genetic signature
Our results with histone-binding mutants of p33ING1 strongly





Fig. 5 Lack of senescence induction in a cancer-associated ING1 mutant. (A) Western blot showing the expression of ectopic AU5-tagged wild-type p33ING1
(ING1) or the C215S mutant. Actin was used as a loading control. (B) Growth curves of IMR-90 fibroblasts expressing the indicated vectors. (C) Percentage of
SA-BetaGal-positive cells after infection of IMR-90 fibroblasts with the indicated vectors, at day 6 postselection. A representative experiment is shown.
(D) Micrographs showing the morphology and SA-BetaGal staining in IMR-90 fibroblasts infected with the indicated vectors.
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depends on its ability to regulate gene expression through
recognition and establishment of chromatin marks. To investi-
gate the transcriptional signature associated with the induction
of senescence by p33ING1, we performed a genome-wide
expression profile analysis. To this end, early passage IMR-90 fi-
broblasts were infected with vectors encoding wild-type
p33ING1 or the Y212A and W235A mutants. Ras-senescent
fibroblasts were also analyzed, as a control for oncogene-
induced senescence. Total RNA was prepared at a time postse-
lection where the differential effects of each ING1 protein were
evident (Fig. S4A) and used to interrogate whole genome
expression arrays. A subset of 286 genes was differentially
expressed at least twofold in IMR-90 fibroblasts arrested by
wild-type ING1 expression, with respect to vector-infected fi-
broblasts (Table S1). Within this group, 200 genes (70%) were
upregulated in ING1-expressing cells, while 86 genes (30%)
were downregulated. Next, we compared the expression pro-
files caused by wild-type or histone-binding-mutant versions of
p33ING1. Of note, the expression profiles caused by the two
mutants were highly similar (over 69% coincidence). This pat-
tern is in keeping with the expected structural consequences of
the mutations and their impact in senescence. Most impor-
tantly, the expression patterns associated with wild-type or
mutant ING1 could be easily discriminated. For 72% of the
genes associated with wild-type ING1, the expression in both
mutants was different to wild type, raising to 94% in at least
one of the mutants (Fig. 7D, Table S1). In most cases, genes
regulated with wild-type ING1 were unchanged with the
mutants (151 genes, 53%), but we also found some examples
(31 genes, 11%) of opposite regulation in wild type and
mutants that might reflect dominant-negative effects (see for
example CXCR7, upregulated by ING1 and downregulated by
the mutants; or HHIP1, with the reverse pattern (Table S1,
Fig. 7C). Interestingly, although both histone-binding mutants
behaved very similarly in this assay, there were statistically sig-
nificant differences between them, with a higher similarity
between the Y212A mutant and wild-type ING1. These results
closely correlate with the binding affinities for H3K4me3 of
each mutant (Pena et al., 2008). The functional category analy-
sis of ING1-regulated genes identified a significant enrichment
for genes involved in chemokine and cytokine signaling. Nota-
bly, these factors have recently been identified as important
regulators of senescence, as part of the senescence associated
secretory phenotype (SASP) (Acosta et al., 2008; Kuilman et al.,
2008) (Fig. S4B). Next, we compared the set of ING1-specific
genes with those modified in Ras-senescent fibroblasts to iden-
tify common signatures between Ras- and ING1-induced senes-
cence. We found a significant overlap between both signatures
(24% of genes with statistically significant differential expres-
sion, with a FDR of 0.10) and selected a group of 45 genes co-
regulated in Ras-senescent and ING1-senescent cells (Fig. 7A).
Interestingly, although p33ING1 caused both up- and downre-
gulation, the similarity between p33ING1 and Ras was higher
within the set of genes downregulated by ING1 (Fig. 7D). As for
the complete set of ING1-regulated genes, the subset overlap-
ping with Ras also showed a significant enrichment for genes
involved in chemokine and cytokine signaling (Fig. 7B; Acosta
et al., 2008; Kuilman et al., 2008). The differential expression
(A)
(B)
Fig. 6 Connection of ING1 with SAHFs.
(A) Percentage of SAHF-positive cells in IMR-90
fibroblasts infected with the indicated vectors. The
average and SD from three experiments is shown.
(B) Confocal fluorescence images showing
subcellular localization of endogenous ING1 in
Ras-senescent IMR-90 fibroblasts. SAHFs are
visualized as hyperchromatic foci in the DAPI
staining.
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results from the microarray analysis were successfully validated
for a selection of genes, using real-time quantitative PCR
(Fig. 7C). To test the direct involvement of ING1 in the tran-
scriptional regulation of these genes, we performed chromatin
immunoprecipitation (ChIP) assays for two of the genes of the
ING1 signature, CXCL2 and TMEM16C. ChIP assays showed
specific binding of ectopic p33ING1 to chromatin in promoter
regions of both genes in ING1-senescent fibroblasts (Fig. 7E).
Of note, in both cases, ING1 binding was detected within a
genomic region enriched in H3K4me3 marks in IMR90 cells
(http://neomorph.salk.edu/human_methylome/browser.html).





Fig. 7 Genetic signature of ING1-induced senescence. (A) Heat-map representation of gene expression profiles of genes with differential expression in ING1-
infected fibroblasts, no regulation with ING1 mutants and overlapping expression with Ras-infected fibroblasts (see text for details). (B) Functional enrichment
analysis of the subset of genes represented in A. The fold enrichment of the indicated set relative to total genome is represented for each category. Statistical
significance was determined with a Fisher’s exact test using the FatiGO application (C). Validation by real-time quantitative PCR of a selection of genes identified in
the microarray analysis. The expression relative to vector-infected controls is shown. In each case, the relative expression data obtained from the array is shown for
reference. The average and SD from three independent QPCR assays is shown. (D) Venn diagram of genes with differential expression in IMR-90 with wild-type
p33ING1 (ING1), relative to the Y212A mutant (Y), the W235A mutant (W), both mutants together (Y ⁄W) or RasV12 (RAS). The data corresponds to the 50 genes
most up- or downregulated in each set. Red numbers indicate upregulated genes and green numbers, downregulated genes. (E) Chromatin immunoprecipitation
showing binding of ectopic p33ING1 to promoter regions of CXCL2 and TMEM16C. The graph shows the percentage of input immunoprecipitated with the AU5
antibody for each locus in vector (V) or AU5-p33ING1 (ING1) infected fibroblasts, after substraction of background (nonspecific antibody precipitation). The
average and SD from triplicates are shown.
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specific genetic signature, which partially overlaps with that of
Ras-induced senescence, with a strong presence of genes of
the senescent secretory phenotype.
Discussion
The products of the ING1 locus participate in the control of cel-
lular processes relevant to tumor protection, such as apoptosis,
cell-cycle arrest, or DNA repair (Soliman & Riabowol, 2007;
Coles & Jones, 2009; Menendez et al., 2009). Alterations of
the ING1 locus are frequent in different types of human tumors
(Nouman et al., 2003; Ythier et al., 2008), indicating an impor-
tant role in tumor suppression. Likewise, mice genetically defi-
cient in the Ing1 locus show increased predisposition to
lymphoma formation (Kichina et al., 2006; Coles et al., 2007).
Senescence is increasingly recognized as an essential tumor-
suppressive mechanism (Campisi & d’Adda di Fagagna, 2007;
Prieur & Peeper, 2008; Collado & Serrano, 2010). Therefore,
identifying the mechanism by which tumor suppressors engage
the senescent response is highly relevant to understand how
they prevent tumor formation, and the impact of their altera-
tions in human tumors. The link between ING proteins and
cellular senescence has been previously investigated (Garkavt-
sev & Riabowol, 1997; Goeman et al., 2005; Pedeux et al.,
2005; Abad et al., 2007; Soliman et al., 2008; reviewed in
Menendez et al., 2009). However, these studies have
frequently led to conflicting results, and the role of specific ING
isoforms or the precise mechanisms involved have remained
unclear. Here, we have used cell-based gain and loss of func-
tion approaches, combined with expression profiling to dissect
the role of p33ING1 in senescence. Collectively, our results
identify ING1 as a critical epigenetic regulator of oncogene-
induced senescence in human fibroblasts. We show that
p33ING1 accumulates in chromatin during oncogene-driven
senescence, ectopic p33ING1 triggers a senescent phenotype,
and RNA interference against p33ING1 impairs growth inhibi-
tion by the MEK oncogene. From a mechanistic point of view,
one of the major conclusions of our work is that chromatin-
mediated gene regulation has an essential role in senescence
control by ING1. ING1 participates in gene regulation via the
recognition of the chromatin mark H3K4me3 and recruitment
of histone-modifying complexes (Champagne & Kutateladze,
2009). We show here that the independent mutation of two
residues essential for H3K4me3 binding abolishes ING1’s ability
to induce senescence. Biophysical and biochemical studies with
ING1 and the close homolog ING2 indicate that the Y212 and
W235A mutations used in this study specifically impair binding
to H3K4me3, but they do not disrupt folding or interaction
with partners (Pena et al., 2006, Pena et al., 2008; Shi et al.,
2006). Supporting this notion, we find that all the ING1
mutants used in our study (Y212A, W235A, C215S) retain the
ability to coprecipitate with p53, an interaction critical for ING1
tumor-suppressive action (Fig. S5). Thus, our data establish a
clear correlation between H3K4me3 recognition and senes-
cence induction by ING1. Previous reports have revealed an
important role in senescence for a number of proteins involved
in the establishment or recognition of chromatin marks, like
BMI (Jacobs et al., 1999), CBX7 and 8 (Gil et al., 2004; Dietrich
et al., 2007), JMJD3 (Barradas et al., 2009), or Suv39H (Braig
et al., 2005). ING proteins are highly specific readers of
H3K4me3 marks. Genetic alterations that result in aberrant
addition, removal, or reading of this chromatin mark are fre-
quent in leukemias and solid tumors (Chi et al., 2010). How-
ever, evidence of direct involvement of H3K4me3 regulators in
senescence is scarce. The MLL1 methylase (Kotake et al., 2009)
and the dual H3K4me3 ⁄H3K36me de-methylases JHDM1A
and JHDM1B (He et al., 2008; Pfau et al., 2008) are mediators
of oncogene and replicative senescence, via the regulation of
the Ink4a ⁄Arf locus. To our knowledge, ING proteins (this
report and Pedeux et al., 2005) are the only examples of spe-
cific H3K4me3 readers involved in senescence, further underly-
ing the importance of proper regulation of this mark in the
context of chromatin dynamics in senescence.
Transcriptional repression of some loci during senescence
occurs in heterochromatin domains known as SAHFs (Narita
et al., 2003, 2006). ING1 has been linked to transcriptional
repression (Kuzmichev et al., 2002; Goeman et al., 2005), and
we show here that it accumulates in senescent chromatin.
However, ING1 does not appear to be a stable component of
the SAHFs. Rather, it was found consistently excluded from
the SAHFs and frequently enriched in its periphery. Of note,
H3K4me3 is also excluded from the SAHFs (Narita et al.,
2003). Two hypothesis consistent with ING1’s bivalent role as
reader of active chromatin marks and component of repressor
complexes (Champagne & Kutateladze, 2009) could be con-
sidered. p33ING1 might contribute to define the boundaries
between SAHFs and active chromatin. Alternatively, it might
participate in the dynamic switch between transcriptional acti-
vation and repression in euchromatin of senescent nuclei. Fur-
ther experiments are needed to identify the precise
mechanism linking ING1 to chromatin domains in senescent
cells.
Our expression analysis has allowed us to define a distinct
genetic signature for ING1-induced senescence of human
fibroblasts, which partially overlaps with that associated to
Ras-induced senescence. Interestingly, this common signature
is enriched in mediators of cytokine and chemokine signaling.
Cytokines and chemokines play critical roles in different aspects
of normal physiology and pathology, including inflammation,
immune response, or tumor growth and metastasis (Mantovani
et al., 2008; Lazennec & Richmond, 2010; Schetter et al.,
2010). Cytokines and chemokines can induce proliferation of
tumor or normal cells (Mantovani et al., 2008), but they can
also promote senescence (Acosta et al., 2008; Coppe et al.,
2008; Kuilman et al., 2008; Wajapeyee et al., 2008; Rodier
et al., 2009) defining the so-called SASP or senescence-
messaging secretome (SMS) (Kuilman & Peeper, 2009). Our
data suggest that the pro-senescence action of ING1 in primary
fibroblasts is largely mediated by the activation of a secretory
response, similarly to other senescence triggers. ING1, like
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other ING proteins, can cooperate with NF-kappaB in transcrip-
tional control (Garkavtsev et al., 2004; Gomez-Cabello et al.,
2010), and putative NF-kappaB sites are present in many genes
of the ING1 signature (data not shown). Interestingly, NF-kap-
paB is an important player in gene regulation during senes-
cence, in part as a regulator of SASP ⁄ SMS genes (Bernard
et al., 2004; Acosta et al., 2008; Wang et al., 2009). Collec-
tively, our results are consistent with a model where ING1 con-
tributes to SASP ⁄ SMS gene expression during senescence, in
cooperation with NF-kappaB.
The ING protein ING2 has also been implicated in cellular
senescence. Similarly to p33ING1, ING2 can trigger senescence
in a p53-dependent manner (Pedeux et al., 2005), but conflict-
ing results have been described for the silencing of ING2
(Pedeux et al., 2005; Kumamoto et al., 2008). Interestingly,
ING2 is the ING protein most closely related to p33ING1, and
they are associated to similar transcriptional repressor com-
plexes (Doyon et al., 2006). It is feasible that regulation of
senescence is a common feature of this subclass of ‘repressor
INGs’, and it would be interesting to determine whether
the role of ING2 in senescence involves a chromatin-related
mechanism, as with ING1.
While chromatin-mediated regulation appears to be the
essential feature for induction of senescence by ING1, other
mechanisms might also play a role. DNA damage caused by
hyperproliferation, telomere dysfunction, or other stimuli can
activate senescence (Campisi & d’Adda di Fagagna, 2007; Colla-
do et al., 2007). We have found evidence of a DNA damage
response in ING1-expressing cells but this response was very lim-
ited and, more importantly, did not correlate with the ability to
induce senescence of the different ING1 versions tested
(Fig. S6).
Our results also show that the implementation of senescence
by p33ING1 requires an intact p53 pathway. The p53 pathway
plays an essential role in senescence control in different settings.
In the case of the human fibroblasts, the Rb pathway plays a
similar role and concomitant inactivation of both pathways is
required to bypass senescence (Campisi & d’Adda di Fagagna,
2007; Collado et al., 2007). There are conflicting results about
the dependence on p53 of the biologic functions of ING1 in vivo
or in vitro (Coles & Jones, 2009). Most likely, the link between
ING1 and p53 is context dependent. In this respect, our data
clearly indicate that implementation of senescence by ING1 in
this cell type is fully dependent on p53, and therefore represents
an example of a p53-dependent function of ING1 linked to
tumor protection.
ING1 can be altered by different mechanisms in human can-
cer, including missense point mutations in a subset of tumors
(Ythier et al., 2008). We find that a version of p33ING1 carrying
a cancer-associated mutation was ineffective in induction of
senescence. This is the first direct evidence of the association
between senescence and tumor-specific alterations in ING1.
Taken together with the independent observation of defective
apoptosis in other tumor-associated ING1 mutants (Pena et al.,
2008), our results strongly indicate that the ability to implement
cellular senescence is a requisite for an effective tumor-protec-
tive action by ING1, further supporting the notion that apoptosis




IMR-90 primary human diploid fibroblasts were obtained from
the American Type Culture Collection (ATCC; Manassas, VA,
USA) and grown in Dulbecco¢s modified Eagle¢s medium (GIB-
CO, Grand Island, NY, USA) supplemented with 10% fetal calf
serum and containing antibiotics, at 37 C in 5% CO2. As
exceptions, IMR-90 cells infected with the E6 oncoprotein were
grown in medium with 20% fetal bovine serum, and IMR-90
expressing an inducible form of MEK1 (MEK1:ER) were cultured
in DMEMwithout Phenol Red (GIBCO).
Mutagenesis
Mutant versions of p33ING1 were generated using the Quick
Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA), using as a template the ORF of the human p33ING1 pro-
tein cloned in the retroviral vector pLPC (Goeman et al., 2005).
Specific mutations were incorporated by PCR using Pfu Turbo
DNA Polymerase (Stratagene), and they were confirmed by
sequencing.
RNA interference vectors
For the generation of shRNAmirs, we used the LMP vector
(Dickins et al., 2005, a gift from S. Lowe, CSHL, USA) that allows
the production of specific shRNAs using a miR30 microRNA
backbone. The cloning of the ING1b-specific sequence into the
LMP vector was performed following the recommended proto-
cols (http://www.openbiosystems.com). The ING1b sequence
targeted was ACCTTTCGACTTGCAGAGAAAT (nucleotides 77–
99, relative to the AUG).
Retroviral transduction
We used early passage IMR-90 with < 30 PDL (Population Dou-
bling Level) in all our experiments. We performed retroviral
transduction with amphotropic and ecotropic viruses. In the
latter case, IMR-90 cells were previously infected with a virus
driving the expression of the ecotropic receptor. Retroviral
infection was performed essentially as described in Goeman
et al., 2005, with minor modifications. In brief, for the produc-
tion of virus, 293T cells were transiently transfected with 10 lg
of pCLEco or pCLAmpho vector (which express the viral genes
gag, pol and envEco or envAmpho) and 10 lg of the vector of
interest. Forty-eight hours later, the supernatant containing the
viral particles was diluted 1 in 2 with fresh medium, filtered,
and polybrene was added to a final concentration of
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8 lg mL)1. This supernatant was added to IMR-90 cells, seeded
the previous day at a concentration of 8 · 105 cells per 10-cm
dish. This procedure was repeated 12 h later using 4 lg mL)1
of polybrene and 24 h later using 8 lg mL)1. After 24 h of
recovery with fresh medium, cells were subjected to antibiotic
selection (2 lg mL)1 of Puromycin or 400 mg mL)1 of G418)
for a period of 3–6 days.
Growth curves
Infected cells were seeded in duplicate a day after the end of
selection at a density of 20 000 cells per well in 24-well plates.
At the indicated time points, cells were trypsinized and counted.
In the case of MEK1-inducible IMR-90 cells, following infection
with the shRNA-mir vectors and selection, cells were treatedwith
1mM of 4-OHT (Sigma, St Louis, MO, USA), or with an equivalent
amount of ethanol. Cells were trypsinized and counted at the
indicated time points, after beginning of treatment.
Senescence-associated Beta-Galactosidase activity
assay
Infected and selected IMR-90 cells were seeded in 6-well plates
at a density of 40 000 cells per well. The day after, cells were
fixed and stained for SA-BetaGal activity as previously described
(Dimri et al., 1995). At least 200 cells were counted to measure
the percentage of SA-BetaGal-positive cells.
BrdU incorporation assay
IMR-90 cells were plated in 8-well glass chamber slides (LabTek,
Rochester, NY, USA), at 30 000 cells per chamber). Twenty-four
hours later, cells were incubated for 6 h with 10 lM BrdU. BrdU-
positive cells were detected by immunofluorescence using an
anti-BrdU antibody (1:1000 dilution; Megabase Research Prod-
ucts, Lincoln, NE, USA). Cells were costained with DAPI to visual-
ize nuclei. To determine the percentage of BrdU-positive cells,
at least 200 nuclei were counted.
Immunofluorescence
Cells were seeded in chamber slides as above-mentioned at a
density of 30 000 cells per chamber. Twenty-four hours later,
they were processed essentially as described in (Gonzalez et al.,
2006). We used the following antibodies: AU5 (1:500, MMS-
135R Covance, Princeton, NJ, USA), ING1 (LG1, a rabbit poly-
clonal against the C-terminus of the human p33ING1 protein;
1:500), gamma-H2AX (1:500, JBW301; Upstate, Billerica, MA,
USA).
Western blot
Preparation of total lysates andWestern blot analysis was carried
out as previously described (Palmero et al., 2002). Chromatin
was isolated as described (Narita et al., 2006). The antibodies
used were p53 (1:500, DO-1; Santa Cruz, Santa Cruz, CA, USA),
ING1 (LG1, 1:1000), p21CIP1 (1:500, C19, Santa Cruz), Ras
(1:2000, OP-40; Calbiochem, Darmstadt, Germany), and AU5
(1:500, MMS-135R: Covance), Acetylated histone H3 (1:1000;
Upstate), Phospho-ATM (1:1000, 05-740; Upstate).
Quantitative PCR
Total RNA was isolated from asynchronously growing IMR-90
cells using Tri Reagent (Sigma). Two micrograms of total RNA
was used to synthesize cDNA using M-MLV reverse transcriptase
(Promega, Madison, WI, USA). One microgram of reaction was
used to perform standard PCR or quantitative PCRs. For quanti-
tative PCR of ING1 transcripts, the following primers were used:
ING1exon1b Forward, GGACTACCTGGACTCCAT; ING1exon1a
Forward, TCGGAGACAGTTTCAGGC; ING1exon2 Reverse,
CGACTGAAGCGCTCGTA; GAPDH Forward, CAGAAGACTGT-
GGATGG; GAPDH Reverse, GCTTCACCACCTTCTTG. For valida-
tion of microarray results, the following primers were used,





GAGTCTCA, GGCAGATCATTTGGTGCTCT; HHIP, TTCACAA-
ACTTGTTCAAAGTGGA, ATGCGAGGCTTAGCAGTCC. The 18S
ribosomal RNA was used as internal reference. For quantitation
of ChIP, the following primers were used: CXCL2, CAGGCGG-
TTATCTCGGTATCTC, CTTTTATGCATGGTTGGGGC; TMEM16C,
TCACTTCTTTGGGTATCGGGT, CACAGGGGCTGAAAAAACAC.
Microarray gene expression profiles
Microarray experiments were performed using Human Whole
Genome 4X44K array G4112F (Agilent Technologies, Santa
Clara, CA, USA). Two independent retroviral infections were
performed in early passage IMR-90 fibroblasts with wild-type
p33ING1, W235A and Y212A ING1 mutants, RasV12 and empty
vector. Total RNA from the different cell populations was
extracted as previously described (Moreno-Bueno et al., 2009).
RNA was labeled and hybridized to arrays using the Low RNA
Linear Amplification Kit and the In Situ Hybridization Kit Plus
(Agilent Technologies), respectively. Competitive hybridization
was performed for each sample, using as a reference a reverse-
labeled sample from vector-infected cells. After hybridization
and washing, the slides were scanned in an Axon GenePix Scan-
ner (Axon Instruments Inc., Union City, CA, USA) and analyzed
using Feature Extraction Software 10.0 (Agilent Technologies).
Two different RNA samples obtained from each condition were
labeled with Cy5-dUTP. The RNA samples from control, vector-
infected cells were labeled with Cy3-dUTP (Agilent Technolo-
gies). Two additional hybridizations were performed using the
reciprocal fluorochrome labeling. For the identification of genes
with differential expression in IMR90 cells expressing p33ING1
with respect to control cells, we used the GEPAS gene expression
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analysis package (http://gepas3.bioinfo.cipf.es) and selected
those genes whose signal differed by a factor of at least twofold
in all of the samples with a standard deviation lower than 0.5.
This subset was further analyzed with respect to their expression
in the rest of samples. Functional enrichment analysis was
performed using the FatiGO application (http://babelomics.
bioinfo.cipf.es/).
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed essen-
tially as described in Gomez-Cabello et al., 2010. from IMR-90
fibroblast infected with AU5-tagged p33ING1 or empty vector.
Immunoprecipitation was carried out with an anti-AU5 antibody
or an isotype-matched nonspecific mouse IgG.
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